AU5044298A - Neuron and neural tumour growth regulatory system, antibodies thereto and uses thereof - Google Patents

Neuron and neural tumour growth regulatory system, antibodies thereto and uses thereof

Info

Publication number
AU5044298A
AU5044298A AU50442/98A AU5044298A AU5044298A AU 5044298 A AU5044298 A AU 5044298A AU 50442/98 A AU50442/98 A AU 50442/98A AU 5044298 A AU5044298 A AU 5044298A AU 5044298 A AU5044298 A AU 5044298A
Authority
AU
Australia
Prior art keywords
neuron
antibodies
tumour growth
regulatory system
growth regulatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU50442/98A
Inventor
Peter Erich Braun
Samuel David
Lisa Joan Mckerracher
Zhi-Cheng Xiao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ZHI CHENG XIAO
Original Assignee
ZHI CHENG XIAO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ZHI CHENG XIAO filed Critical ZHI CHENG XIAO
Publication of AU5044298A publication Critical patent/AU5044298A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4725—Proteoglycans, e.g. aggreccan
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU50442/98A 1996-11-15 1997-11-17 Neuron and neural tumour growth regulatory system, antibodies thereto and uses thereof Abandoned AU5044298A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CA 2190418 CA2190418A1 (en) 1996-11-15 1996-11-15 Neuron and neural tumor growth regulatory system, antibodies thereto and uses thereof
CA2190418 1996-11-15
PCT/CA1997/000868 WO1998022499A2 (en) 1996-11-15 1997-11-17 Arretin, a neurite outgrowth modulator, antibodies thereto and uses thereof

Publications (1)

Publication Number Publication Date
AU5044298A true AU5044298A (en) 1998-06-10

Family

ID=4159259

Family Applications (1)

Application Number Title Priority Date Filing Date
AU50442/98A Abandoned AU5044298A (en) 1996-11-15 1997-11-17 Neuron and neural tumour growth regulatory system, antibodies thereto and uses thereof

Country Status (3)

Country Link
AU (1) AU5044298A (en)
CA (1) CA2190418A1 (en)
WO (1) WO1998022499A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3134799A (en) * 1998-04-16 1999-11-08 Peter Erich Braun Nevron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
WO2002014537A2 (en) 2000-08-14 2002-02-21 Fallon Joan M Methods for diagnosing and treating dysautonomia and other dysautonomic conditions
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
WO2006111348A1 (en) * 2005-04-18 2006-10-26 Abbott Gmbh & Co. Kg Use of heparin and heparin derivatives for modulating the neurite growth-controlling nogo receptor
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
PL2318035T3 (en) 2008-07-01 2019-10-31 Curemark Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
CA2747611C (en) 2009-01-06 2019-09-17 Curemark Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
BRPI1007379B8 (en) 2009-01-06 2022-07-19 Curemark Llc pharmaceutical compositions for the treatment or prevention of oral infections by e. coli
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
GB2503852B (en) 2011-04-21 2018-12-12 Curemark Llc Compounds for the treatment of neuropsychiatric disorders
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2141600A1 (en) * 1992-08-03 1994-02-17 Richard U. Margolis Cloning, expression and uses for neurocan as a chondroitin sulfate proteoglycan
JPH07509002A (en) * 1993-02-11 1995-10-05 エルツィーヒュングスディレクション　オブ　ザ　キャントン　チューリッヒ Combination of neurotrophins and antibodies against myelin-related axonal growth inhibitory protein promotes central nervous system regeneration
US5625040A (en) * 1994-01-27 1997-04-29 The Research Foundation Of State University Of New York Phosphacan: a chondroitin sulfate proteoglycan of brain that interacts with neurons and neural cell adhesion molecules
GB9403250D0 (en) * 1994-02-21 1994-04-13 Univ Mcgill Therapeutic use of myelin-associated glycoprotein (mag)
WO1995026201A1 (en) * 1994-03-28 1995-10-05 La Jolla Cancer Research Foundation Brevican, a glial cell proteoglycan
AU5264496A (en) * 1995-04-13 1996-10-30 Mount Sinai Hospital Corporation Modulator of neuronal cell response to inhibition by cns mye lin
WO1996032959A1 (en) * 1995-04-19 1996-10-24 Acorda Therapeutics Cns neurite outgrowth modulators, and compositions, cells and methods embodying and using same

Also Published As

Publication number Publication date
CA2190418A1 (en) 1998-05-15
WO1998022499A2 (en) 1998-05-28
WO1998022499A3 (en) 1998-07-30

Similar Documents

Publication Publication Date Title
AU5044298A (en) Neuron and neural tumour growth regulatory system, antibodies thereto and uses thereof
AU2653199A (en) Pseudospontaneous neural stimulation system and method
AU3993093A (en) Neural network based control system
AU6017994A (en) Language-sensitive collation system
EP0682834A4 (en) Intelligent broadband communication system and method.
AU6267896A (en) Antibody and antibody fragments for inhibiting the growth oftumors
AU7105296A (en) Personal identification system
AU4303596A (en) System for the selective distribution of assets between internal portfolios
AU7163796A (en) Security system
AU3675295A (en) Tamper-evident closure system
AU3817097A (en) Universal system for artificial intelligence based learning, categorization, and optimization
AU3855495A (en) Cat litter-tray
AU7229396A (en) Transport system
AU3001500A (en) Method and system for artificial intelligence directed lead discovery through multi-domain clustering
AU7451391A (en) Programming system and method, and programming device and terminals constituting the system
AUPO370596A0 (en) Vegetation recognition system
AUPN211395A0 (en) The continuous mining, transport and treatment system
AU701166B2 (en) Pelletizing plant
AU5468896A (en) Polypeptides, their production and use
AU4483696A (en) Novel peptides, their production and use
AU4674596A (en) Complexes, processes for their preparation and their use
ZA965872B (en) Wheels and tyres.
AU6191398A (en) Method for the identification and therapeutic use of disease-associated organisms, elements and forces
AU5597696A (en) Treatment system
AU7506796A (en) Biological neural network